Latest Infliximab Stories

WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to responses from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab (both interleukin inhibitors) will capture 22 percent of the biologics share in 2012 in the drug market for moderate to severe psoriasis. Among these two agents, Stelara will experience greater...

EXTON, Pa., Dec. 14 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive insight into the management of RA patients. The report is based on a comparison of self-reported treatment approaches (as reported by 208 Rheumatologists) with actual patient level data for over 1,000 RA patients who are currently being treated with biologic agents. To be eligible for the audit, patients had to...

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6...

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight http://www.reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Competitive-Landscape-and-Pipeline-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent...

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition http://www.reportlinker.com/p0158357/Biotech-in-Autoimmune-and-Inflammatory-Disease-2006-2nd-Edition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Despite their diversity, global healthcare systems are increasingly converging in the need and desire to contain costs of...

WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare...

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to...

Overall cancer risk comparable to those not taking immunosuppressive drugsA recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab,...

SAN DIEGO, Oct. 26 /PRNewswire/ -- According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study. These exploratory data...

WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in...